Pract Neurol. 2018 Nov 29. pii: practneurol-2018-001899. doi: 10.1136/practneurol-2018-001899. Rituximab is a widely used B-cell-depleting monoclonal antibody. It is unlicensed for use in neurological disorders…
By Kelly Davio Antibodies that deplete B cells, including rituximab, have demonstrated efficacy in the treatment of neurological conditions such as progressive multiple sclerosis (MS) and neuromyelitis optica spectrum…
J Neuroinflammation. 2016 Sep 27;13(1):280. Jarius S1, Ruprecht K2, Kleiter I3, Borisow N4,5, Asgari N6, Pitarokoili K3, Pache F4,5, Stich O7, Beume LA7, Hümmert MW8,…
JAMA Neurol. 2013 Sep 1;70(9):1110-7. Kim SH, Huh SY, Lee SJ, Joung A, Kim HJ. IMPORTANCE: A previous 2-year analysis of repeated rituximab treatment in…
Rev Neurol (Paris). 2016 Mar;172(3):220-4. doi: 10.1016/j.neurol.2015.12.004. Epub 2016 Feb 23. Romero G, Ticchioni M, Cohen M, Rosenthal-Allieri MA, Mondot L, Lebrun Frenay C. Neuromyelitis…
Neurotherapeutics. 2016 Jan;13(1):70-83. doi: 10.1007/s13311-015-0400-8. Kleiter I, Gold R. Neuromyelitis optica spectrum disorders (NMOSD) are important evolving entities, which have reached much attention in the…
J Clin Neurosci. 2016 Apr;26:168-70. doi: 10.1016/j.jocn.2015.08.033. Epub 2015 Dec 15. Dai Y1, Lu T1, Wang Y1, Fang L1, Li R1, Kermode AG2, Qiu W3….
Autoimmune diseases Monday, April 02, 2012, 17:30 – 19:00 Autologous haematopoietic stem cell transplantation in aggressive forms of neuromyelitis optica (NMO) and NMO spectrum disorders Raffaella Greco, Lucia Moiola, Paolo Rossi, Marta Radaelli, Daniela Ungaro, Massimo Bernardi, Consuelo Corti, Jacopo Peccatori, Attilio Bondanza, Maria Teresa Lupo Stanghellini, Giancarlo Comi, Fabio Ciceri (Milan, IT) ——————————————————————————– Background.
Rituximab dosing and monitoring strategies in neuromyelitis optica patients: creating strategies for therapeutic success Benjamin M Greenberg Donna Graves Gina Remington Paula Hardeman Martha Mann Nitin Karandikar Olaf Stuve Nancy Monson Elliot Frohman University of Texas Southwestern Medical Center, Dallas, TX, USA Benjamin M. Greenberg, MD, MHS, University of Texas Southwestern Medical Center, 5323 Harry Hines Boulevard, Dallas, TX 75390-8806, USA. Email: benjamin.greenberg@utsouthwestern.edu Abstract Background: Neuromyelitis optica (NMO) is an autoimmune condition that predominantly causes severe optic neuritis and transverse myelitis.
Variable results after rituximab in neuromyelitis optica. Lindsey JW, Meulmester KM, Brod SA, Nelson F, Wolinsky JS. Abstract Our objective was to assess the efficacy of rituximab (RTX) in neuromyelitis optica (NMO)
Multiple sclerosis: treatment Tuesday, May 31, 2011, 11:30 – 12:30 Safety and efficacy of rituximab in neuromyelitis optica spectrum disorder M. Radaelli, L. Moiola, D
OBJECTIVE: To investigate an association between serum B cell activating factor of TNF family (BAFF) levels and anti-aquaporin-4 (AQP4) antibody titers in patients with neuromyelitis optica (NMO) after rituximab treatment. BACKGROUND: Anti-AQP4 antibodies are present in approximately 70% of NMO patients. Such antibodies are probably pathogenic and the titers are elevated during relapse as compared with those in remission.